CSPC Pharmaceutical Group Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Simply Wall St · 1d ago

A week ago, CSPC Pharmaceutical Group Limited (HKG:1093) came out with a strong set of quarterly numbers that could potentially lead to a re-rate of the stock. The company beat expectations with revenues of CN¥6.7b arriving 2.0% ahead of forecasts. Statutory earnings per share (EPS) were CN¥0.087, 8.4% ahead of estimates. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on CSPC Pharmaceutical Group after the latest results.

earnings-and-revenue-growth
SEHK:1093 Earnings and Revenue Growth November 20th 2026

Following the recent earnings report, the consensus from 23 analysts covering CSPC Pharmaceutical Group is for revenues of CN¥30.7b in 2027. This implies a noticeable 2.1% decline in revenue compared to the last 12 months. Statutory earnings per share are expected to plummet 20% to CN¥0.52 in the same period. Before this earnings report, the analysts had been forecasting revenues of CN¥30.5b and earnings per share (EPS) of CN¥0.51 in 2027. The analysts seems to have become more bullish on the business, judging by their new earnings per share estimates.

Check out our latest analysis for CSPC Pharmaceutical Group

The consensus price target was unchanged at HK$12.57, implying that the improved earnings outlook is not expected to have a long term impact on value creation for shareholders. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. The most optimistic CSPC Pharmaceutical Group analyst has a price target of HK$19.00 per share, while the most pessimistic values it at HK$8.00. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. Over the past five years, revenues have declined around 0.9% annually. Worse, forecasts are essentially predicting the decline to accelerate, with the estimate for an annualised 1.7% decline in revenue until the end of 2027. Compare this against analyst estimates for companies in the broader industry, which suggest that revenues (in aggregate) are expected to grow 9.6% annually. So it's pretty clear that, while it does have declining revenues, the analysts also expect CSPC Pharmaceutical Group to suffer worse than the wider industry.

The Bottom Line

The biggest takeaway for us is the consensus earnings per share upgrade, which suggests a clear improvement in sentiment around CSPC Pharmaceutical Group's earnings potential next year. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that CSPC Pharmaceutical Group's revenue is expected to perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple CSPC Pharmaceutical Group analysts - going out to 2028, and you can see them free on our platform here.

You still need to take note of risks, for example - CSPC Pharmaceutical Group has 2 warning signs (and 1 which is a bit unpleasant) we think you should know about.